Similar reductions in neutropenia duration have been demonstrated in other retrospective studies evaluating the effects of G-CSF or GM-CSF treatment (Andrès et al., 2002; Beauchesne and Shalansky, 1999). This evidence concerns the gene CSF3 and neutropenia.